[Skip to Content]
[Skip to Content Landing]
September 4, 1972

Doxorubicin in Disseminated

Author Affiliations

From the departments of medicine A (Drs. Cortes and Holland) and pediatrics (Drs. Wang and Sinks), Roswell Park Memorial Institute, Buffalo.

JAMA. 1972;221(10):1132-1138. doi:10.1001/jama.1972.03200230020005

Doxorubicin (adriamycin) is a new cytotoxic antibiotic with antitumor activity in a variety of neoplasms in man. Thirteen patients with pulmonary metastases from osteogenic sarcoma were given adriamycin at a dose ranging from 17.5 to 35 mg/sq m of body surface area daily for three or four days, repeated at monthly intervals. Of these, one patient had complete remission; three, partial remissions; and one improvement by 25% tumor regression was also obtained. Toxic manifestations of adriamycin administration were pancytopenia, capital alopecia and hair loss from other parts of the body, stomatitis, and nausea and vomiting. Adriamycin appears to be effective therapy for disseminated osteogenic sarcoma, and the toxic reactions from its administration do not preclude the practical application of the drug in the treatment of this usually fatal neoplasm.